Search academic texts

Information × Registration Number 0303U009135, 0102U006902 , R & D reports Title A double-blind, placebo-controlled, randomized, multinational study to investigate the safety and efficacy of 2 mg TID of Cilancetron over 26 weeks in diarrhea-predominant irritable bowel syndrom subjects popup.stage_title Подвійне сліпе, плацебо-контрольоване рандомізоване багатоцентрове дослідження оцінки безпеки застосування 2 мг циланцетрона тричі на день протягом 26 тижнів у хворих з синдромом подразненої товстої кишки з нахилом до діареї Head Svintsitskiy A., Registration Date 25-12-2003 Organization National Medical University popup.description2 According to inclusion criteria the patients with in diarrhea-predominant irritable bowel syndrom were selected. The check-ups of these patients were conducted during the 26 weeks period of Cilansetron or placebo intake. The results were sent to the customer for further analysis. Product Description popup.authors popup.nrat_date 2020-04-02 Close